Bellicum out-licenses safety switch technology to MD Anderson; shares up

Nano cap Bellicum Pharmaceuticals (BLCM +14.6%) is up on 60% higher volume on the heels of its out-licensing deal with MD Anderson Cancer Center for its CaspaCIDe safety switch technology.

Under the terms of the agreement, Bellicum will receive $5M upfront, undisclosed milestones and royalties on net sales.

CaspaCIDe is designed to protect patients receiving cell-based therapies from cytokine release syndrome or neurotoxicity.

https://seekingalpha.com/news/3525598-bellicum-out-licenses-safety-switch-technology-to-md-anderson-shares-up-15